We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current FULC market cap is 200.31M. The company's latest EPS is USD -1.5598 and P/E is -2.06.
| Quarter End | Mar 2023 | Jun 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 295k | 1.18M | 871k | 0 | 80M |
| Operating Income | -27.94M | -55.23M | -27.99M | -29.83M | 52.49M |
| Net Income | -24.78M | -48.56M | -24.76M | -26.87M | 55.41M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 8.82M | 19.16M | 6.34M | 2.81M |
| Operating Income | -84.22M | -71.61M | -81.05M | -112.56M | -110.66M |
| Net Income | -89.81M | -70.82M | -80.85M | -109.87M | -97.34M |
| Quarter End | Mar 2023 | Jun 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 321.12M | 300.33M | 257.69M | 232.59M | 294.26M |
| Total Liabilities | 24.86M | 24.9M | 22.5M | 19M | 20.47M |
| Total Equity | 296.26M | 275.43M | 235.19M | 213.59M | 273.79M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 110.44M | 129.58M | 235M | 226.69M | 257.69M |
| Total Liabilities | 23.29M | 34.4M | 23.46M | 27.74M | 22.5M |
| Total Equity | 87.15M | 95.18M | 211.54M | 198.94M | 235.19M |
| Quarter End | Mar 2023 | Jun 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -24.12M | -44.9M | -90.97M | -25.28M | 33.62M |
| Investing | -93.94M | -74.07M | -36.69M | 38.13M | 25.62M |
| Financing | 117.69M | 117.84M | 118.12M | 1.65M | 2.03M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -39.48M | -53.66M | -78.48M | -97.05M | -90.97M |
| Investing | -944k | -57.14M | -129.67M | 12.41M | -36.69M |
| Financing | 64.34M | 71.13M | 186.51M | 84.32M | 118.12M |
| Market Cap | 200.31M |
| Price to Earnings Ratio | -2.06 |
| Price to Sales Ratio | 71.56 |
| Price to Cash Ratio | 7.86 |
| Price to Book Ratio | 0.85 |
| Dividend Yield | - |
| Shares Outstanding | 62.4M |
| Average Volume (1 week) | 481.87k |
| Average Volume (1 Month) | 599.9k |
| 52 Week Change | -11.81% |
| 52 Week High | 13.70 |
| 52 Week Low | 2.865 |
| Spread (Intraday) | 0.32 (9.14%) |
| Company Name | Fulcrum Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.fulcrumtx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
